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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERChildhood Obesity and Cardiovascular Dysfunction 1309Anita T. Cote, Kevin C. Harris, Constadina Panagiotopoulos, George G. S. Sandor, Angela M. Devlin
Obesity-related cardiovascular disease in children is becoming more prevalent in conjunction
with a rise in childhood obesity. This state-of-the-art paper reviews the spectrum of
cardiovascular abnormalities observed in children with obesity and highlights the importance
and need for early detection and prevention programs.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYCovered Stents Versus BMS for Complex Superﬁcial Femoral Artery Lesions 1320
Johannes Lammer, Thomas Zeller, Klaus A. Hausegger, Philipp J. Schaefer, Manfred Gschwendtner,
Stefan Mueller-Huelsbeck, Thomas Rand, Martin Funovics, Florian Wolf, Aljoscha Rastan,
Michael Gschwandtner, Stefan Puchner, Robin Ristl, Maria Schoder
The authors evaluated the hypothesis that heparin-bonded covered stents (Viabahn,WLGore,
Flagstaff, Arizona) are superior to bare-metal stents (BMS) for the treatment of long
femoropopliteal artery disease. A total of 141 patients with symptomatic peripheral arterial
disease (PAD) were assigned to treatment with heparin-bonded covered stents (n ¼ 72) or
BMS (n ¼ 169). Mean lesion length was 19.0  6.3 cm in the Viabahn group versus 17.3 
0.6 cm in the BMS group. The 12-month primary patency rates in the Viabahn and BMS
groups were 78.1% and 53.5%, respectively (hazard ratio: 2.23). Patients with lesions 20 cm
had a primary patency rate of 73.3% when treated with Viabahn versus 33.3% when treated
with BMS. Freedom from target lesion revascularization was 84.6% in the Viabahn group
versus 77.0% in the BMS group. The authors conclude that, for symptomatic PAD patients
undergoing endovascular treatment for long popliteal lesions, heparin-bonded covered stents
demonstrate signiﬁcant clinical and patency beneﬁts compared with BMS.
Editorial Comment: John R. Laird, Ehrin J. Armstrong, p. 1328(continued on page A-32)
OCTOBER 8, 2013 (continued) A-32HEART FAILUREIvabradine and Exercise Capacity in HFpEF 1330
Wojciech Kosmala, David J. Holland, Aleksandra Rojek, Leah Wright,
Monika Przewlocka-Kosmala, Thomas H. Marwick
This study tested the effects of treatment with ivabradine on exercise capacity and left
ventricular ﬁlling in patients with heart failure with preserved ejection fraction (HFpEF).
A total of 61 patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily
(n ¼ 30) or placebo (n ¼ 31) for 7 days. The ivabradine group demonstrated a signiﬁcant
improvement between baseline and follow-up exercise capacity (4.2  1.8 metabolic
equivalents [METs] vs. 5.7  1.9 METs) and peak oxygen uptake (14  6.1 ml/min/kg vs.
17.0  3.3 ml/min/kg) with a simultaneous reduction in exercise-induced increase in peak
early diastolic mitral annular velocity (E/e0) (3.1  2.7 vs. 1.3  2.0). Therapy with
ivabradine and change with treatment in exertional increase in E/e0 were independent
correlates of the increase in METs, and therapy with ivabradine independently correlated
with the increase in peak oxygen uptake. The authors show that in patients with HFpEF,
short-term treatment with ivabradine increased exercise capacity, with a contribution from
improved left ventricular ﬁlling pressure response to exercise, as reﬂected by the E/e0 ratio.
Editorial Comment: Sanjiv J. Shah, p. 1339HEART RHYTHM DISORDERSBeta-Blockers and Inappropriate ICD Therapy 1343
Martin H. Ruwald, Abeer Abu-Zeitone, Christian Jons, Anne-Christine Ruwald,
Scott McNitt, Valentina Kutyifa, Wojciech Zareba, Arthur J. Moss
This study evaluated the effects of carvedilol and metoprolol on inappropriate implantable
cardioverter-deﬁbrillator (ICD) therapy in all patients enrolled in the MADIT-CRT
(Multicenter Automatic Deﬁbrillator Implantation With Cardiac Resynchronization
Therapy) study who received a device. Effect of the type of beta-blocker or no beta-blocker
on inappropriate therapy, deﬁned as antitachycardia pacing (ATP) or shock, were compared.
Inappropriate therapy occurred in 253 of 1,790 patients (14%) during a mean follow-up of
3.4 years. Treatment with carvedilol was associated with a signiﬁcantly decreased risk of
inappropriate therapy when compared with metoprolol (hazard ratio [HR]: 0.6). The risk of
inappropriate therapy caused by atrial ﬁbrillation was also reduced in patients taking
carvedilol compared with metoprolol (HR: 0.50). The results reveal that in heart failure
patients with either cardiac resynchronization therapy with a deﬁbrillator or ICD device,
carvedilol was associated with a 36% reduction of inappropriate ATP or shock therapy.
Inappropriate therapy due to atrial ﬁbrillation was reduced by 50% in patients taking
carvedilol compared with metoprolol.
Editorial Comment: Merritt H. Raitt, p. 1351(continued on page A-33)
OCTOBER 8, 2013 (continued) A-33CARDIAC IMAGINGCAD Detection by Myocardial Contrast Echocardiography Vs. SPECT 1353Roxy Senior, Antonella Moreo, Nicola Gaibazzi, Luciano Agati, Klaus Tiemann,
Bharati Shivalkar, Stephan von Bardeleben, Leonarda Galiuto, Hervé Lardoux, Giuseppe Trocino,
Ignasi Carrió, Dominique Le Guludec, Gianmario Sambuceti, Harald Becher, Paolo Colonna,
Folkert ten Cate, Ezio Bramucci, Ariel Cohen, Gianpaolo Bezante, Costantina Aggeli,
Jaroslaw D. Kasprzak
The objective of this study was to compare sulfur hexaﬂuoride microbubble (SonoVue,
Bracco Imaging SpA, Milan, Italy)-enhanced myocardial contrast echocardiography (MCE)
with single-photon emission computed tomography (SPECT) relative to coronary
angiography for the assessment of coronary artery disease (CAD). Of the patients referred for
myocardial ischemia testing, 516 patients underwent all 3 examinations. A total of 161
(31.2%) had 70% stenosis and 310 (60.1%) had 50% stenosis on coronary angiography.
For patients with 70% stenosis, higher sensitivity was obtained on MCE versus SPECT
(75% vs. 49%), although speciﬁcity was lower (52% vs. 81%). Similar results were obtained
for 50% stenosis and in subgroup analysis (single vs. multivessel disease, prior myocardial
infarction, proximal disease, and so on). The authors conclude that SonoVue-enhanced
MCE demonstrated superior sensitivity, but lower speciﬁcity, for detection of CAD when
compared with SPECT in a population with a high incidence of cardiovascular risk factors
and an intermediate to high prevalence of CAD. They proposed the presence of
microvascular disease as a possible explanation for the lower speciﬁcity of MCE relative to
SPECT.
Editorial Comment: James D. Thomas, p. 1362BIOMARKERSPrevention of Events by NT-proBNP–Selected Therapy in Diabetics 1365
Martin Huelsmann, Stephanie Neuhold, Michael Resl, Guido Strunk, Helmut Brath,
Claudia Francesconi, Christopher Adlbrecht, Rudolf Prager, Anton Luger, Richard Pacher, Martin Clodi
The authors evaluated the primary preventive effect of neurohormonal therapy in high-risk
diabetic patients selected by N-terminal pro–B-type natriuretic peptide (NT-proBNP). A
total of 300 patients with type 2 diabetes and elevated NT-proBNP (>125 pg/ml) but free of
cardiac disease were randomized to either the “control” group or the “intensiﬁed” group that
underwent additional uptitration of RAS (renin-angiotensin system) antagonist or beta-
blocker in an outpatient cardiac clinic. The primary endpoint was hospitalization/death due
to cardiac disease after 2 years. At baseline, the mean age of patients was 67.5  9 years,
duration of diabetes was 15  12 years, and median NT-proBNP was 265 pg/ml. There was
a signiﬁcant reduction of the primary endpoint (hazard ratio: 0.35) in the intensiﬁed group.
The same was true of other endpoints: all-cause hospitalization and unplanned cardiovascular
hospitalization/death. Accelerated uptitration of the RAS antagonist and the beta-blocker to
a maximum tolerated dosage is an effective and safe intervention for the primary prevention
of cardiac events for diabetic patients pre-selected using NT-proBNP.
Editorial Comment: G. Michael Felker, Tariq Ahmad, p. 1373(continued on page A-34)
OCTOBER 8, 2013 (continued) A-34GENETICS/GENOMICSChromosome 9p21.3 Locus for CAD: How Little We Know 1376
Clett Erridge, Jay Gracey, Peter S. Braund, Nilesh J. Samani
The mechanism responsible for the association between common variants in chromosome
9p21.3 and coronary artery disease (CAD) remains unclear. The objective of this study was to
determine whether the CAD-associated genotype at chromosome 9p21 modulates basal or
induced expression of type-I interferons (IFN-I). The authors examined whether the
genotype at the lead CAD-associated single nucleotide polymorphism (rs. 1333049) in 9p21
was associated with: 1) basal levels of IFN-I in plasma from 148 healthy male subjects; 2)
induction of IFN-I by Toll-like receptor stimulants in peripheral blood mononuclear cells of
60 healthy volunteers assessed by enzyme-linked immunosorbent assay, quantitative
polymerase chain reaction, Western blot, and IFN-I bioassay; and 3) enhancer activity of
predicted interferon regulatory factor 3/7 binding sites within the 9p21 CAD risk region in
reporter assays. No signiﬁcant effects of 9p21 genotype were observed for any of the
parameters studied. These results show that the mechanism underlying the association
between common 9p21 variants and CAD does not involve differential regulations of IFN-I
response.
Editorial Comment: Ruth McPherson, p. 1382HEART VALVE DISEASEEmbolic Risk in Endocarditis 1384
Sandrine Hubert, Franck Thuny, Noemie Resseguier, Roch Giorgi, Christophe Tribouilloy,
Yvan Le Dolley, Jean-Paul Casalta, Alberto Riberi, Florent Chevalier, Dan Rusinaru,
Dorothée Malaquin, Jean Paul Remadi, Ammar Ben Ammar, Jean Francois Avierinos,
Frederic Collart, Didier Raoult, Gilbert Habib
The objective of this study was to develop and validate a simple calculator to quantify the
embolic risk (ER) at admission of patients with infective endocarditis (IE). From 1,072
consecutive patients presenting with a deﬁnite diagnosis of IE in a multicenter observational
cohort study, 847 were randomized into derivation (n ¼ 565) and validation (n ¼ 282)
samples. The 6-month incidence of embolism was similar in the development and validation
samples (8.5% in 2 samples). Six variables were associated with the ER and were used to
create the calculator: age, diabetes, atrial ﬁbrillation, embolism before antibiotics, vegetation
length, and Staphylococcus aureus. There was an excellent correlation between the predicted
and observed ER both in the development and validation samples (c-statistics were 0.22 and
0.65, respectively). The authors conclude that the risk of embolism during IE can be
quantiﬁed at admission by a simple and accurate calculator.
